stockrow
Friday 6 November 2026
Export RYTM’s income statement to Excel — free account
Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
112.38
7.36
+7.01%
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Revenue growth
Rhythm Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 61.0%, up 15.2 percentage points from fiscal 2025 (45.8%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 45.8% | (22.23) |
| FY2024 | 68.1% | (159.50) |
| FY2023 | 227.6% | (421.90) |
| FY2022 | 649.5% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 79.6% | 32.68 |
| Jun 2026 | 46.9% | (36.90) |
| Mar 2026 | 83.8% | 46.94 |
| Dec 2025 | 36.9% | (17.41) |
| 15 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| PRAX Praxis Precision Medicines, Inc. compare | 249.5% |
| RYTM Rhythm Pharmaceuticals, Inc. | 61.0% |
| AXSM Axsome Therapeutics, Inc. compare | 54.2% |
| CORT Corcept Therapeutics Incorporated compare | 30.0% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 16.1% |
| IONS Ionis Pharmaceuticals, Inc. compare | −7.41% |
| ABVX Abivax SA Sponsored ADR compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement